Creative Bioarray, the world’s leading biotechnology products and services provider, today announced the expansion of its innovative oncology models which include Syngeneic models, Patient-derived Xenograft (PDX) Models, and Humanized Mouse Models etc. This marks a significant milestone in the development of Creative Bioarray’s innovative preclinical platform for — oncology drug discovery services.
Cancer research relies highly on representative and reliable model systems. However, cancer is not a tumor defined by a single molecule, but a heterogeneous and highly variable complex of different diseases, which makes the study of cancer very difficult and requires a lot of resources. The models used in cancer research are constantly changing and extend to all stages of drug discovery, including target identification, lead structure optimization, biomarker analysis, tolerance, toxicity, and individual patient prediction.
Creative Bioarray offers a broad range of well-characterized xenograft, patient-derived xenograft (PDX), syngeneic tumor models as well as genetically engineered mouse models (GEMMs). If the mechanism of action needs to be implemented in the complete immune system, the setting of immunosuppression required by the xenograft model will not be suitable for efficacy evaluation. In this case, a syngeneic model in which the derived tumor cell line and the host animal strain are the same may be more appropriate. Creative Bioarray has established multiple syngeneic models, including breast cancer, lung cancer, colon cancer, and melanoma and lymphoma models.
With an advanced research platform and superb technical team, Creative Bioarray can provide a variety of syngeneic tumor models in multiple formats and is committed to assisting in experimental projects to accelerate research. Syngeneic tumor models are allografts derived from immortalized mouse cancer cell lines, which are derived from the same mouse inbred line. These models are crucial for new immune-based therapies by providing valuable systems for evaluating new single drugs and allowing us to study the way cancer therapies are combined with the functional immune system.
The syngeneic tumor models offered by Creative Bioarray can be widely applied in the research of drug screening, ranging from immuno-based therapy development, therapeutic effect evaluation to drug development.
“Creative Bioarray has one of the most extensive collections of isogenic tumor models in the industry, and we specialize in in situ implantation. Our model is well characterized and benchmarked against the most common immune checkpoint inhibitors and other immunomodulators and combination therapies.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Our in-house experts are dedicated to assisting our clients in conducting their experimental projects to accelerate research. Using our syngeneic mouse model, customers can inquire about novel immunotherapies and combination therapies.”
About Creative Bioarray
Creative Bioarray is a global drug discovery and development service company providing professional platforms to advance oncology, drug development, and many other disease research. With an extensive portfolio of relevant oncology models and predictive tools, Creative Bioarray enables clients to deliver superior clinical candidates. For more information, visit: https://www.creative-bioarray.com/.
Release ID: 88963625